Cargando…

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines

Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was originally identified in Saudi Arabia in 2012. It has caused MERS outbreaks with high mortality in the Middle East and Europe, raising a serious concern about its pandemic potential. Therefore, development of effective vaccines is cr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Cuiqing, Li, Ye, Wang, Lili, Zhao, Guangyu, Tao, Xinrong, Tseng, Chien-Te K., Zhou, Yusen, Du, Lanying, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194189/ https://www.ncbi.nlm.nih.gov/pubmed/24560617 http://dx.doi.org/10.1016/j.vaccine.2014.02.004

Ejemplares similares

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design
por: Ma, Cuiqing, et al.
Publicado: (2014)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
por: Tang, Jian, et al.
Publicado: (2015)

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
por: Du, Lanying, et al.
Publicado: (2016)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
por: Mao, Tianyang, et al.
Publicado: (2022)

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2016)

Potentiating Lung Mucosal Immunity Through Intranasal Vaccination
por: Nelson, Sean A., et al.
Publicado: (2021)

Calling for rapid development of a safe and effective MERS vaccine
por: Hotez, Peter J., et al.
Publicado: (2014)

Current advancements and potential strategies in the development of MERS-CoV vaccines
por: Zhang, Naru, et al.
Publicado: (2014)

Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection
por: Jiang, Shibo, et al.
Publicado: (2015)

Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
por: Weskamm, Leonie M., et al.
Publicado: (2022)

Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination
por: Vierboom, Michel P.M., et al.
Publicado: (2021)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

MERS-CoV Spike Protein Vaccine and Inactivated Influenza Vaccine Formulated with Single Strand RNA Adjuvant Induce T-Cell Activation through Intranasal Immunization in Mice
por: Kim, Hye-Jung, et al.
Publicado: (2020)

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2013)

Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection
por: Jia, Wenxu, et al.
Publicado: (2019)

MERS-CoV spike protein: Targets for vaccines and therapeutics
por: Wang, Qihui, et al.
Publicado: (2016)

Intranasal Vaccination with Murabutide Enhances Humoral and Mucosal Immune Responses to a Virus-Like Particle Vaccine
por: Jackson, Erin M., et al.
Publicado: (2012)

Editorial: Mucosal Vaccination: Strategies to Induce and Evaluate Mucosal Immunity
por: Kozlowski, Pamela A., et al.
Publicado: (2022)

Intranasal acellular pertussis vaccine provides mucosal immunity and protects mice from Bordetella pertussis
por: Boehm, Dylan T., et al.
Publicado: (2019)

Spiking the MERS-coronavirus receptor
por: Bosch, Berend Jan, et al.
Publicado: (2013)

Advances in mRNA and other vaccines against MERS-CoV
por: Tai, Wanbo, et al.
Publicado: (2022)

A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice
por: Li, Entao, et al.
Publicado: (2019)

Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
por: He, Lei, et al.
Publicado: (2019)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
por: Nyon, Mun Peak, et al.
Publicado: (2018)

Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs
por: Dhakal, Santosh, et al.
Publicado: (2018)

Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
por: An, Xingyue, et al.
Publicado: (2021)

Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity
por: Hartwell, Brittany L., et al.
Publicado: (2022)

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
por: Channappanavar, Rudragouda, et al.
Publicado: (2015)

Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein
por: Al-amri, Sawsan S., et al.
Publicado: (2017)

A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice
por: Niu, Peihua, et al.
Publicado: (2018)

Immunization of MERS-CoV-2-infected mice with a sublethal dose of MERS-CoV or VRP-MERS-S
por: Zheng, Jian, et al.
Publicado: (2023)

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2018)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination
por: Kim, Sae-Hae, et al.
Publicado: (2012)

Sublingual Delivery of Vaccines for the Induction of Mucosal Immunity
por: Shim, Byoung-Shik, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vgtnbf8l35ngns4p8uepn4ihbo